Abstract
The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres.
Original language | English |
---|---|
Pages (from-to) | 738-743 |
Number of pages | 6 |
Journal | Digestive and Liver Disease |
Volume | 45 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- Adalimumab
- Ulcerative colitis
- “Real-life” study